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Human cytomegalovirus (HCMV) able to cause 
infection for an entire lifetime. HCMV is also 
called human herpesvirus 5 (HHV-5) (1). This 
virus exists in body fluids and is transmitted from 
person to person through contact with nasopha-
ryngeal secretions, urine, saliva, semen, cervical 
Abstract 
Background: Human cytomegalovirus (CMV) able to cause infection for an entire lifetime. This systematic 
review and meta-analysis was conducted to determine seroprevalence of CMV among women of reproductive 
age in Iran. 
Methods: English and Persian databases such as Web of Science (WOS), PubMed, Scopus, Cochrane Library, 
SID, Iran doc, Iran Medex, Magiran, and Medlib were searched (from 2008 to 2017) accurately using the key-
words: Cytomegalovirus, Pregnant women or Pregnancy, Epidemiology, Prevalence and Iran. 
Results: Results of 15 studies with total samples of 5253 persons from 2008 to 2017 were combined and meta-
analyzed. The pooled prevalence rate of IgG among women was estimated 90% (95% CI: 87-93%). The highest 
prevalence rate of IgG was in Tehran, Rasht, Mashhad and Yasoj, all 100% (95% CI: 100-100%), and the low-
est prevalence was in Jahrom 0.62% (95% CI: 53-71%). The overall prevalence rate of IgM among women was 
estimated at 0.06% (95% CI: 0.03-0.13%). The highest prevalence rate of IgM was in Kerman 0.34% (95% CI: 
0.29-0.39%) and Mashhad 0.25% (95% CI: 0.2-0.31%), and the lowest prevalence was in Yasoj 0% (95% CI: 
0.00%-0.00%)  
Conclusion: The prevalence of immunity in Iran, is satisfactory. Nevertheless, to maintain and increase the 
level of immunity across the country, it is necessary to routinely screen the women of reproductive ages across 
the country. 
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secretions, or blood (2). The highest prevalence 
of this infection has been observed in Africa, 
Asia, and South America, and the lowest in 
Western Europe and North America (3). The 
prevalence of CMV has been reported to be low 
in Australia, Germany (4) and England (5) while 
it has been reported to be high in countries such 
as Saudi Arabia with a prevalence of 90% (6). 
The prevalence of HCMV antibodies was report-
ed 98% in pregnant women, and 98.3% in non-
pregnant women in Brazil (7).  
Infection with HCMV is one of the most im-
portant causes of death caused by diseases in 
people with immunodeficiency (8, 9). The infec-
tion may be acquired during the embryonic peri-
od (congenital) through the placenta as a result of 
primary infection or recurrent of maternal infec-
tion, or during the perinatal/postnatal period, 
related to cervical secretions, breast milk, or in-
fected blood products (2). HCMV is the most 
common congenital CMV infection, whose prev-
alence rates are identical in developed and devel-
oping countries (10) and is still considered as a 
complicated problem for gynecologists and pedi-
atricians (7). Infectious agents during pregnancy, 
are of particular importance. Because they not 
only threaten the health of pregnant mothers but 
also cause fetal death and congenital abnormali-
ties (11). Maternal infection during pregnancy, 
especially during the first trimester of pregnancy, 
causes risk of acute fetal infection, and neurolog-
ical, auditory, and visual disabilities, which will 
cause a lot of cost and problems (11).  
The information about CMV infection in the 
pregnant women population is very controversial 
(12). Initial infection with CMV occurs at 0.15% 
to 2% of all pregnancies and is transferred to the 
fetus in up to 40% of cases, a number of these 
cases lead to abortions, about 15% to sympto-
matic congenital diseases, and 10%-15% to 
asymptomatic congenital diseases (13). Principal-
ly, infections caused by CMV are more common 
in women, and its risk increases with age (14) but 
in pregnant women, most of the cases (60%-
66%) occur at ages below 30 yr (15). 
Given the importance of the health of pregnant 
women, infants, and children aged 1-59 months 
(as indicators of social health and development), 
as well as the serious consequences of CMV for 
fetus, its screening can be useful during pregnan-
cy (16). Moreover, conducting a comprehensive 
study to assess the prevalence of CMV in these 
age groups across the country can be helpful in 
healthcare planning. The present systematic re-
view and meta-analysis was conducted to deter-
mine the prevalence of CMV infection in women 





In order to determine the prevalence of CMV 
infection in reproductive age women in Iran, the 
current systematic review was designed based on 
published papers limited to both English and 
Persian articles from 2008 to 2017. The following 
English databases were searched: 1) Web of Sci-
ences (WOS); 2) PubMed; 3) Scopus; 4) Embase; 
and 6) Cochrane Library. The Persian databases 
were: 1) Magiran; 2) Scientific Information Data-
base (SID), 3) Iran Medex, 4) Iran doc, and 5) 
Medlib. The databases were searched without 
time restriction. We searched by the Medical Sub-
ject Headings (MeSH) terms such as: "Cytomeg-
alovirus"[MeSH Terms], "Pregnant wom-
en"[MeSH Terms], "Pregnancy"[MeSH 
Terms],"Epidemiology"[MeSH Terms], "Preva-
lence"[MeSH Terms] and "Iran"[MeSH Terms]. 
 
Inclusion and exclusion criteria 
The case-control and cross-sectional studies 
which determined the prevalence of CMV in 
both healthy pregnant women and women in 
their reproductive age following with the serolog-
ical techniques were included in our systematic 
review. Inclusion criteria were: Studies which re-
ported rate of CMV antibodies (IgG & IgM) 
prevalence among an Iranian-based population, 
case-control and cross-sectional studies, healthy 
pregnant women, and women in their reproduc-
tive age. The exclusion criteria were: studies with 
non-random sampling methods, those with spe-
cific populations (HIV-positive individuals, and 
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immunodeficiency patients), studies with no re-
ports of prevalence or insufficient data, studies 
which reported cytomegalovirus incidence among 
non-Iranian nationality, reviews, meeting abstract 




In order to assess the eligibility, all relevant pa-
pers were reviewed by two independent authors 
and contradictions among them were dissolved 
by consensus. The related data were extracted 
using a data extraction checklist on the basis of 
title, city, year of publication, author name, sam-
ple size, number of seropositive cases (IgG+ & 
IgM+) and prevalence of (IgG+ & IgM+) and di-
agnostic methods. 
The checklists of STROBE for the studies were 
classified into three categories which included 
high, intermediate and low quality. Seven items 
from the recommended checklist of STROBE 
were selected and used for assessing the quality 
of studies. The studies were classified as high 
quality if all items were achieved, as intermediate 
quality if they did not achieve one criterion, and 




A pooled estimated prevalence of cytomegalovi-
rus infection was calculated using Der Simonian-
Laird random model (17) and the results were 
reported by 95% confidence interval (CI). To 
examine the heterogeneity between studies, Q-
test and I2 were used (18). Moreover, to examine 
possible factors affecting the prevalence, we used 
relative risk (Relative risk) indicator. To investi-
gate sources of heterogeneity, meta-regression 
based on the year of publication and sample size 
were performed. The sensitivity analysis was per-
formed to ensure stability of the results. Studies 
were ranked according to the year of publication 
and Cumulative meta-analysis was performed. 
Subgroup analysis also performed based on geo-
graphic location, type of study, and the quality of 
studies. Egger test and funnel graph were used to 
evaluate publication bias (19). The data were ana-





Overall, 1120 articles were identified; 1105 arti-
cles were excluded from evaluation due to irrele-
vant data and duplicated researches. Finally, our 
meta-analysis study data covers 15 articles from 
2007 to 2017 (Fig. 1). 
 
General information of samples 
Our systematic review cover women of their re-
productive age without previous exposure to sim-
ilar viral infection recently and they had general 
health.  
 
Prevalence of cytomegalovirus antibodies 
among women  
Results of 15 studies with total samples of 5253 
people from 2008 to 2017 were combined and 
meta-analyzed. The pooled prevalence rate of 
IgG among women was estimated 90% (95% CI: 
87%-93%) (Fig. 2), sensitivity analysis (Fig. 2-A) 
and cumulative meta-analysis (Fig. 2-B) were per-
formed but there was no significant change in the 
overall prevalence. 
The highest prevalence rate of IgG was in Teh-
ran, Rasht, Mashhad and Yasoj, all 100%, (95% 
CI: 100%-100%), and the lowest prevalence was 
in Jahrom 0.62% (95% CI: 53-71%) (Fig. 2) (Ta-
ble 1). 
The overall prevalence rate of IgM among wom-
en was estimated 0.06% (95% CI: 0.03-0.13%). 
The highest prevalence rate of IgM was in Ker-
man 0.34% (95% CI: 0.29-0.39%) and Mashhad 
0.25 % (95% CI: 0.2%-0.31%), and the lowest 
prevalence was in Yasoj 0% (95% CI: 0.00%-
0.00%) (Fig. 3, Table 1). 
Meta-regression result based on year and sample 
size showed in Table 2. The prevalence of IgG 
increased by year significantly (P=0.031). Moreo-
ver, reduction in IgG was seen based on sample 
size but it was not significant (P=0.388).  
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Fig. 2: The forest plot of overall prevalence of IgG among women of reproductive age in Iran 
Iran J Public Health, Vol. 48, No.2, Feb 2019, pp. 206-216 
 
210                                                                                                        Available at:    http://ijph.tums.ac.ir  
 
 




Fig. 2B: The forest plot of the cumulative meta-analysis based on overall prevalence of IgG 
 
Table 1: Characteristics of all eligible studies 
 
No. City Year Study  
population 
Cytomegalovirus seroprevalence (%) Method Reference 
   (n) IgG IgM   
1 Babol 2016 141 0.9645 _ ELISA (27) 
2 Gonabad 2012 240 0.7208 0.25 ELISA (28) 
3 Jahrom 2011 120 0.625 _ ELISA (29) 
4 Kerman 2007 397 0.9193 0.3375 ELISA (11) 
5 Rasht 2014 40 1 0.175 ELISA (30) 
6 Rasht 2013 360 0.7722 0.0138 ELISA (31) 
7 Tehran 2012 100 1 0.03 ELISA (32) 
8 Tehran 2015 98 0.9081 0.1224 ELISA (33) 
9 Yasoj 2015 94 0.9893 0 ELISA (34) 
10 Khoramabad 2011 240 0.9041 _ ELISA (35) 
11 Tabriz 2008 2049 0.8853 0.0003 ELISA (36) 
12 Tabriz 2009 125 0.84 0.064 ELISA (37) 
13 Boshehr 2014 180 0.95 _ ELISA (38) 
14 Mashhad 2014 225 1 0.0266 ELISA (39) 
15 Shiraz 2008 844 0.9052 0.0533 ELISA (40) 
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Fig. 3: The forest plot of overall prevalence of IgM among women of reproductive age in Iran 
 
Table 2: Meta-regression result based on year and sample size of studies 
 
Variable Estimate SE Z P Low CI 95% Upper CI 95% 
Year  0.0110 0.0051 2.1510 0.0315 0.0010 0.0210 
Sample size -0.0000 0.0000 -0.8622 0.3886 -0.0001 0.0000 
intercept -0.0890 0.0187 -4.7581 <.0001 -0.1257 -0.0524 
 
Subgroup analysis for comparison of IgG preva-
lence based on quality of studies, geographical 
regions, and educational level was shown in Ta-
ble 3. Among region subgroups, the lowest and 
highest percentage of positive cases were seen in 
South 0.85% (95% CI=0.77-0.94%) and Center 
0.91% (95% CI=0.87-0.100%) respectively (Ta-
ble 2 and Fig. 4). Among educational level 
subgroups, the lowest and highest percentage of 
positive cases were seen in Under Diploma 0.66 
% (95% CI=0.48%-0.90%) and Academic 0.91 




Fig. 4: Immunity to cytomegalovirus among women of reproductive age in different regions 
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Table 3: Subgroup analysis for comparison of IgG prevalence based on main related factors 
 
Items  No studies Prevalence 95% CI I2 P 
Quality of studies 
Good 7 88% (82-94) 95.1% 0.0001 
Medium  7 91% (86-95) 98.2% 0.0001 
Low  1 95% (92-98) NA NA 
Geographic regions 
North  3 91% (80-100) 96.8% 0.0001 
South  3 85% (77-94) 94.2% 0.0001 
West  4 91% (85-97) 96% 0.0001 
East  3 88% (79-99) 97.9% 0.0001 
Center  2 96% (87-100) 88.3% 0.0034 
Type of study 
Case-control 3 84% (71-100) 96.1% 0.0001 
Cohort 1 91% (89-93) NA NA 
Cross-sectional 11 91% (87-95) 97.4% 0.0001 
Educational level 
Under Diploma 4 66% (48-90) 95.8% 0.0001 
Diploma  4 69% (55-86) 90.7% 0.0001 
Academic  4 71% (56-89) 78.5% 0.0030 
 
Subgroup analysis of the quality of studies ac-
cording to the STROB checklist showed that 
seven studies had Good and Medium quality, and 
one study was of low quality.  
For finding relation between abortion history in 
women with CMV infection, we used RR indica-
tor, but the result showed no significant relation 
(RR=0.75 (95% CI: 0.33%-1.70%). 
Funnel plot diagram of IgG antibodies based on 
Egger’s regression test to detect publication bias 
is shown in Fig.5. The results showed publication 
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Discussion 
 
CMV infection in women of reproductive ages 
causes irreversible complications such as abor-
tions, premature birth, congenital diseases, severe 
neurological complications, and even death, 
which subsequently brings a lot of cost and prob-
lems to the country. The present study is the first 
systematic review and meta-analysis, which deals 
with investigating the prevalence of CMV in 
women of reproductive ages in Iran. 
Overall, based on our meta-analysis, the immuni-
ty against cytomegalovirus in women of repro-
ductive ages in Iran was calculated to be 90% 
(95% CI: 87%-93%) (Fig. 2).  
In China, research on 1023 women, the immunity 
against CMV reported to be 98.7%, which is 
higher than that in our study (20). In addition, a 
study in Nigeria on 179 pregnant women, report-
ed the immunity to be 97.2% (21). This level of 
immunity was also higher than that in Iran. Nev-
ertheless, another study in Sudan on 231 preg-
nant women and the immunity against CMV was 
reported to be 72.2% (22) which is lower than 
that in Iran. In Mexico, the immunity against 
CMV reported to be 65.6%, which is lower than 
that in Iran (23). 
In our study, the highest level of immunity 
against CMV was reported to be in Tehran (2012) 
and Mashhad (2014) with a prevalence of 100%, 
and the lowest immunity level was related to 
Jahrom (2011) with a prevalence of 62%. Proba-
bly, a higher level of immunity is due to a strong-
er first-level care, the more efficient and a larger 
amount of education, the increased level of pub-
lic awareness, better socio-economic conditions, 
and a decreased number of pregnancies, and a 
lower level of immunity due to high-risk sexual 
behaviors, increased cases of transfusion, de-
creased family income, as well as decreased levels 
of education and nursing care. 
A sub-group analysis based on geographic re-
gions showed that the highest level of immunity 
is related to the eastern part (97.9%) and 
northern part of the country (96.8%), and the 
lowest level of immunity to the central part of the 
country (88.3%). Moreover, immunity was calcu-
lated to be 96% in the western part of the coun-
try, and 94.2% in the southern part of the coun-
try. A higher level of immunity is due to the in-
creased level of the people's education and 
awareness, as well as a larger amount of educa-
tion and better socio-economic situation of the 
people. On the other hand, lack of facilities, in-
creased population, decreased level of informing, 
decreased levels of social and cultural facilities, 
decreased level of nursing care quantity and quali-
ty, increased amount of high-risk behaviors, and 
low maternal age at first pregnancy, have resulted 
in the lowest level of immunity in the central part 
of the country. 
IgM is an antibody, whose titer increases before 
IgG, with the onset of illness. This antibody is 
also produced in the stages of reinfection and 
active infection. In our study, the prevalence of 
positive IgM was 0.06% in Iran (Fig. 3), whose 
largest amount belonged to the city of Kerman 
with 32%, and the lowest to the city of Tabriz 
with 0.003%. In the United States, the prevalence 
of CMV was reported to be 1.6% per year, which 
is greater than that in Iran (24). 
A meta-regression based on the year of publica-
tion showed that the immunity against CMV has 
had an increasing trend across Iran during the 
years 2008 to 2017 (Table 2). This increased level 
of immunity is due to the improved socio-
economic situation, the increased level of the 
people's education and awareness, providing in-
formation by the Ministry of Health and it’s pay-
ing more attention to first-level care in the coun-
try in recent years. 
The results of publication bias were significant 
according to Egger's test. The quality of the pa-
pers affects the bias. The quality of 8 papers out 
of 15 papers has been at a medium level in our 
study. Some of the studies have mainly paid at-
tention to pregnant women and married women, 
which could be a reason why publication bias is 
significant in our study. 
In our study, heterogeneity was calculated using 
Q-test and I2, and its level was reported to be 
high. One of the reasons for the increased level 
of heterogeneity can be the small sample size in 
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different studies. In our study, the lowest sample 
size contained 40 samples, and the highest sam-
ple size contained 2,049 samples. 
The results showed that the prevalence of CMV 
was not significantly different between people 
with a history of abortion and normal group. In a 
study in Greece on 102 women who had a histo-
ry of spontaneous abortion of the fetus, there 
were only 4 people infected with cytomegalovirus 
(CMV), and no statistically significant relation-
ship was observed between CMV and spontane-
ous abortion of the fetus (25). In a study con-
ducted on 60 women with a history of abortion, 
they came to the conclusion that only 9 women 
(15%) out of those with a history of spontaneous 
abortion of the fetus, were infected with CMV 
(26). The results of these studies did not approve 
the relationship between CMV infection and 
abortion and were consistent with the results of 
our study. 
Another factor which can be effective in the im-
munity against CMV is the education level. A 
subgroup analysis based on the education level 
showed that the highest level of immunity was 
related to the education level lower than high 
school diploma with 95.8%, and the lowest level 
of immunity was related to academic education 
with 78.5%. In Sudan, the level of immunity 
against cytomegalovirus was lower in lower edu-
cational levels (22). Moreover, the level of im-
munity against cytomegalovirus was reported to 
be higher in people with higher levels of educa-
tion, which is not consistent with our study (21). 
Perhaps, these results are due to the small sample 
size in studies conducted in Iran, as well as the 





Overall, the prevalence of immunity in Iran is 
satisfactory. Nevertheless, to maintain and in-
crease the level of immunity across the country, it 
is necessary to routinely screen the women of 
reproductive ages across the country. In addition, 
in the provinces where the prevalence of infec-
tion has not been measured so far, it should be 
assessed and reported. Due to its irreversible ne-
onatal complications, CMV testing should be-
come obligatory during pregnancy, to prevent the 
birth of children with severe neurological prob-
lems. The prevalence of CMV infection is higher 
at early ages, it is necessary to begin teaching how 
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